옵션 체인은 다양한 행사가격과 만기일에 대한 Twist Bioscience의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Twist Bioscience에 대한 시장 심리를 평가합니다..

Twist Bioscience (NASDAQ:TWST) 주식, 옵션 체인

Twist Bioscience

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Mid Cap

News

Movers

ALHC

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 1. 쾨르 마이닝(NYSE:CDE)의 주식은 36.59% 상승했다. 이 회사는 네바다주에 확장된 로체스터(Rochester) 은-금 광산의 처리량 추세가 긍정적이라고 보고했다.

쾨르 마이닝, 뉴 골드 및 RH는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (9월 8일-9월 14일)

Equities

Markets

$BTC

ARKF

ARKW

AVAV

DKNG

GLBE

RDDT

RKLB

STNE

TWLO

TWOU

수요일에 캐시 우드의 아크 인베스트(Ark Invest)는 몇 가지 중요한 거래를 했다. 그 중 가장 눈에 띄는 것은 쇼피파이(NYSE:SHOP), 레딧(NYSE:RDDT)의 주식 매수, 그리고 코인베이스 글로벌(NASDAQ:COIN)의 주식 매각이다.

아크 인베스트는 쇼피파이 주식 $3,000만 이상 매입, 레딧도 매수, 코인베이스 주식은 매도

Twist Bioscience Corporation - Common Stock

Twist Bioscience Corp

WIIM

RARE

Ultragenyx Pharmaceutical Sees FY24 Revenue $530M-$550M Vs $536.8M Est

<p><strong>Share Repurchase Program:</strong></p>
<p>The Company's board of directors (the "Board") has approved a new share repurchase program (the "2024 Share Repurchase Program") pursuant to which the Company is authorized to repurchase up to $100.0 million in shares of the Company's common stock, inclusive of fees and commissions. This program replaces the Company's previous share repurchase program adopted in 2021, under which $9.4 million remained available for repurchase. The 2024 Share Repurchase Program is effective immediately and does not have an expiration date.</p>
<p>Repurchases under the 2024 Share Repurchase Program may be made, from time to time, in amounts and prices the Company deems appropriate and may be made pursuant to a trading plan intended to qualify under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Repurchases by the Company under the 2024 Share Repurchase Program will be subject to general market and economic conditions, applicable legal requirements and other considerations. The 2024 Share Repurchase Program may be suspended, modified or discontinued by the Board at any time without prior notice at the Company's discretion.</p>


Buybacks

Grocery Outlet Holding Corp. Has Approved A New Share Repurchase Program Pursuant To Which The Company Is Authorized To Repurchase Up To $100M In Shares Of The Company's Common Stock,

<p>Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $3.221 billion which Beat the analyst consensus estimate. This is a 11.54 percent decrease over sales of $3.64 billion the same period last year.</p>


Earnings

Earnings Misses

LUMN

Lumen Technologies Q3 2024 Adj EPS $(0.13) Misses $(0.09) Estimate, Sales $3.221B Beat $3.218B Estimate

<p>Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.18) by 144.44 percent.  The company reported quarterly sales of $854.000 thousand which missed the analyst consensus estimate of $6.477 million by 86.81 percent.  This is a 24.85 percent increase over sales of $684.000 thousand the same period last year.</p>


EOSE

Eos Energy Enterprises Q3 2024 Adj. EPS $(0.44) Misses $(0.18) Estimate, Sales $854.000K Miss $6.477M Estimate

<p>Momentum investing is all about the idea of following a stock&#39;s recent trend, which can be in either direction. In the &#39;long&#39; context, investors will essentially be &quot;buying high, but hoping to sell even higher.&quot; And for investors following this methodology, taking advantage of trends in a stock&#39;s price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.</p>
<p>Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the <a href="https://www.zacks.com/education/stock-style-scores/momentum-trading" target="_blank">Zacks Style Scores</a>, helps address this issue for us.</p>
<p>Below, we take a look at <strong>U.S. Bancorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usb#NYSE">USB</a>)</strong>, which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.</p>
<p>It&#39;s also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. U.S. Bancorp currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.</p>
<h3>Set to Beat the Market?</h3>
<p>In order to see if USB is a promising momentum pick, let&#39;s examine some Momentum Style elements to see if this company holds up.</p>
<p>Looking at a stock&#39;s short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It&#39;s also helpful to compare a security to its industry; this can show investors the best companies in a particular area.</p>
<p>For USB, shares are up 0.21% over the past week while the Zacks Banks - Major Regional industry is up 0.33% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 6.12% compares favorably with the industry&#39;s 4.51% performance as well.</p>
<p>While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of U.S. Bancorp have risen 13.79%, and are up 33.8% in the last year. On the other hand, the S&amp;P 500 has only moved 7.29% and 32.85%, respectively.</p>
<p>Investors should also pay attention to USB&#39;s average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. USB is currently averaging 8,694,755 shares for the last 20 days.</p>
<h3>Earnings Outlook</h3>
<p>The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with USB.</p>
<p>Over the past two months, 6 earnings estimates moved higher compared to 1 lower for the full year. These revisions helped boost USB&#39;s consensus estimate, increasing from $3.86 to $3.92 in the past 60 days. Looking at the next fiscal year, 8 estimates have moved upwards while there have been 1 downward revision in the same time period.</p>
<h3>Bottom Line</h3>
<p>Given these factors, it shouldn&#39;t be surprising that USB is a #2 (Buy) stock and boasts a Momentum Score of B. If you&#39;re looking for a fresh pick that&#39;s set to soar in the near-term, make sure to keep U.S. Bancorp on your short list.</p>
<p><a href="https://www.zacks.com/stock/news/2364640/u-s-bancorp-usb-is-a-great-momentum-stock-should-you-buy?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_10-2364640">To read this article on Zacks.com click here.</a></p>
<p><a href="https://www.zacks.com/">Zacks Investment Research</a></p>


Trading Ideas

General

U.S. Bancorp Is A Great Momentum Stock: Should You Buy?

Contracts

Eos Energy Announced A New Agreement With City Utilities To Provide 216 MWh Of Energy Storage For Two Project Sites In Missouri: Terms Not Disclosed

<p>National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) sees Q4 sales of $82.000 million-86.000 million vs $89.27 million estimate.</p>


Guidance

NCMI

National CineMedia Sees Q4 Sales $82.000M-86.000M vs $89.27M Est.

<p><strong>Outlook:</strong></p>
<p>The Company is updating key guidance figures for fiscal 2024 as follows:</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>Previous</td>
<td>Current</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>New store openings, net(2)</td>
<td>62 to 64</td>
<td>66</td>
</tr>
<tr>
<td>Net sales</td>
<td>$4.30 billion to $4.35 billion</td>
<td>slightly above $4.35 billion</td>
</tr>
<tr>
<td>Comparable store sales increase</td>
<td>~3.5%</td>
<td>~2.4%</td>
</tr>
<tr>
<td>Gross margin</td>
<td>~30.5%</td>
<td>~30.4%</td>
</tr>
<tr>
<td>Adjusted EBITDA(1)</td>
<td>$252 million to $260 million</td>
<td>$237 million to $242 million</td>
</tr>
<tr>
<td>Adjusted diluted earnings per share(1)</td>
<td>$0.89 to $0.95</td>
<td>$0.77 to $0.80</td>
</tr>
<tr>
<td>Capital expenditures (net of tenant improvement allowances)</td>
<td>~$200 million</td>
<td>~$200 million</td>
</tr>
</tbody>
</table>
<p></p></figure></p>


Grocery Outlet Holding Corp. Updates FY24 EPS Guidance From $0.89-$0.95 To $0.77-$0.80 Vs $0.88 Est.; Revenue From $4.30B-$4.35B To Slightly Above $4.35B Vs $4.37B Est.

<p>Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) reported quarterly earnings of $0.02 per share. This is a 230.77 percent increase over losses of $(0.01) per share from the same period last year.  The company reported quarterly sales of $56.00 million which missed the analyst consensus estimate of $57.30 million by 2.28 percent.  This is a 10.60 percent increase over sales of $50.63 million the same period last year.</p>


VTEX

Vtex Q3 EPS $0.02 Up From $(0.01) YoY, Sales $56.00M Miss $57.30M Estimate

<p>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) reported quarterly losses of $(1.40) per share which beat the analyst consensus estimate of $(1.53) by 8.5 percent.  The company reported quarterly sales of $139.494 million which beat the analyst consensus estimate of $135.794 million by 2.72 percent.  This is a 42.27 percent increase over sales of $98.052 million the same period last year.</p>


Earnings Beats

Ultragenyx Pharmaceutical Q3 2024 GAAP EPS $(1.40) Beats $(1.53) Estimate, Sales $139.494M Beat $135.794M Estimate

<p>United Fire Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFCS#NASDAQ">UFCS</a>) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.33 by 145.45 percent.  The company reported quarterly sales of $322.964 million which beat the analyst consensus estimate of $306.800 million by 5.27 percent.  This is a 17.89 percent increase over sales of $273.955 million the same period last year.</p>


UFCS

United Fire Gr Q3 2024 Adj. EPS $0.81 Beats $0.33 Estimate, Sales $322.964M Beat $306.800M Estimate

<p>On a day when global attention focused on the U.S. presidential election, Israeli Prime Minister <strong>Benjamin Netanyahu </strong>announced the dismissal of defense minister <strong>Yoav Gallant</strong>, amid a crisis of trust over differences in managing <a href="https://www.benzinga.com/topic/israel-hamas-war">Israel's war efforts in Gaza</a>.</p>
<p>Gallant, who had held the defense minister post since 2022, has been a key figure in Israel&#8217;s response to the ongoing conflicts against Hamas and Iran-backed Hezbollah. </p>
<p>According to Netanyahu&#8217;s remarks, the relationship between the two deteriorated in recent months, fueled by what the prime minister described as significant gaps in their approach to the war effort.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/news/24/10/41348633/emmanuel-macron-has-sharp-words-for-israels-pm-mr-netanyahu-must-not-forget-that-his-country-was-cre">Emmanuel Macron Has Sharp Words For Israel&#8217;s PM: &#8216;Mr. Netanyahu Must Not Forget That His Country Was Created By A UN Decision&#8217;</a></strong></p>
<p>"I tried to bridge these gaps, but they kept getting wider," Netanyahu said in a statement. He argued that the trust issues had become "public domain," a development that he claimed was exploited by Israel's adversaries. </p>
<p>Gallant, for his part, responded to the firing on X, formerly known as Twitter. He expressed unwavering commitment to Israel's safety.</p>
<p>"The security of the State of Israel was and will always remain the mission of my life," he wrote.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="iw" dir="rtl">ביטחון מדינת ישראל היה ותמיד יישאר משימת חיי &#x1f1ee;&#x1f1f1;&#x1f1ee;&#x1f1f1;</p>
<p>&mdash; יואב גלנט &#8211; Yoav Gallant (@yoavgallant) <a href="https://twitter.com/yoavgallant/status/1853862189888602366?ref_src=twsrc%5Etfw">November 5, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>In place of Gallant, Netanyahu has appointed <strong>Israel Katz</strong>, a seasoned politician who has held multiple cabinet positions, including minister of foreign affairs, minister of finance, and minister of intelligence.</p>
<p>&#8220;He is known as a bulldozer with a combination of responsibility and firmness, quiet firmness, and all of these are very important for managing the campaign,&#8221; Netanyahu said about Katz.</p>
<p>Additionally, Netanyahu revealed discussions with minister without portfolio Gideon Sa'ar, inviting him to join the coalition as Foreign Minister.</p>
<h3 class="wp-block-heading">Market Reactions: Oil, Israeli Stocks Rise</h3>
<p>News of Gallant's dismissal and the internal discord in Israel's wartime leadership had a marginal impact on financial markets, with traders fully focused on the upcoming results from U.S. elections. </p>
<p>West Texas Intermediate (WTI) light crude, tracked by the <strong>United States Oil Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), was 0.6% up to $72.2 a barrel as of 3:10 p.m. ET on Tuesday, holding earlier gains during the session and marking its second consecutive day in the green.</p>
<p>Israeli stocks saw a slight boost Tuesday, with the <strong>VanEck Israel ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRA#NYSE">ISRA</a>) climbing 0.8%.</p>
<p><strong>Now Read</strong>:</p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41753325/wall-street-rallies-on-election-day-palantir-skyrockets-bitcoin-tops-70-000-whats-driving-">Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What&#8217;s Driving Markets Tuesday?</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Emerging Markets

Emerging Market ETFs

Commodities

Politics

ISRA

Israel's Netanyahu Fires Defense Minister Gallant Over Lack Of Trust in War Management, Oil Prices Rise As Election Results Loom

<p><strong>MariMed</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-11-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that MariMed will report an <strong>earnings per share</strong> (EPS) of $-0.01. </p>
<p>MariMed bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.01, leading to a 3.43% increase in the share price the following trading session.</p>
<p>Here's a look at MariMed's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.01</td>
<td>-0.01</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0</td>
<td>0</td>
<td>0.004</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840556_0.png" alt="eps graph" /></p>
<h3>Performance of MariMed Shares</h3>
<p>Shares of MariMed were trading at $0.1629 as of November 04. Over the last 52-week period, shares are down 49.97%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MRMD/earnings"><strong>To track all earnings releases for MariMed visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MRMD

Exploring MariMed's Earnings Expectations

<p>Stewart Information Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STC#NYSE">STC</a>) will release its quarterly earnings report on Wednesday, 2024-10-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Stewart Information Servs to report an <strong>earnings per share</strong> (EPS) of $1.04.</p>
<p>The market awaits Stewart Information Servs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.22, which was followed by a 1.13% drop in the share price the next day.</p>
<p>Here's a look at Stewart Information Servs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.04</td>
<td>1.13</td>
<td>-0.13</td>
<td>0.53</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.17</td>
<td>0.91</td>
<td>0.17</td>
<td>0.60</td>
<td>0.86</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840549_0.png" alt="eps graph" /></p>
<h3>Market Performance of Stewart Information Servs's Stock</h3>
<p>Shares of Stewart Information Servs were trading at $67.63 as of November 04. Over the last 52-week period, shares are up 53.05%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Stewart Information Servs</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Stewart Information Servs.</p>
<p>With 1 analyst ratings, Stewart Information Servs has a consensus rating of Neutral. The average one-year price target is $75.0, indicating a potential 10.9% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of  and Trupanion, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for  and Trupanion, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trupanion</td>
<td>Neutral</td>
<td>14.55%</td>
<td>$49.38M</td>
<td>0.46%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Stewart Information Servs ranks in the middle among peers for Revenue Growth and Gross Profit, with a growth rate of 14.55% and gross profit of $49.38M. However, it lags behind in terms of Return on Equity, standing at 0.46%. The consensus rating for the company is neutral.</p>
<h3>About Stewart Information Servs</h3>
<p>Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.</p>
<h3>Unraveling the Financial Story of Stewart Information Servs</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Stewart Information Servs showcased positive performance, achieving a revenue growth rate of <strong>10.91%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Stewart Information Servs's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>4.51%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Stewart Information Servs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.17%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Stewart Information Servs's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.12%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.4</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/STC/earnings"><strong>To track all earnings releases for Stewart Information Servs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Stewart Information Servs's Earnings Outlook

<p>Granite Point Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPMT#NYSE">GPMT</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Granite Point Mortgage to report an <strong>earnings per share</strong> (EPS) of $-0.82.</p>
<p>Anticipation surrounds Granite Point Mortgage's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.16, which was followed by a 4.46% drop in the share price the next day.</p>
<p>Here's a look at Granite Point Mortgage's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.21</td>
<td>0.02</td>
<td>-0.29</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.05</td>
<td>0.03</td>
<td>0.14</td>
<td>0.18</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-13.0%</td>
<td>-7.000000000000001%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840537_0.png" alt="eps graph" /></p>
<h3>Market Performance of Granite Point Mortgage's Stock</h3>
<p>Shares of Granite Point Mortgage were trading at $3.01 as of November 04. Over the last 52-week period, shares are down 35.43%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GPMT/earnings"><strong>To track all earnings releases for Granite Point Mortgage visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GPMT

Granite Point Mortgage's Earnings: A Preview

<p><strong>Tutor Perini</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-11-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Tutor Perini will report an <strong>earnings per share</strong> (EPS) of $-1.89. </p>
<p>The market awaits Tutor Perini's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 26.81% drop in the share price the following trading session.</p>
<p>Here's a look at Tutor Perini's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.19</td>
<td>-0.17</td>
<td>0.13</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.19</td>
<td>0.30</td>
<td>-0.91</td>
<td>-0.71</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-27.0%</td>
<td>28.000000000000004%</td>
<td>23.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840530_0.png" alt="eps graph" /></p>
<h3>Performance of Tutor Perini Shares</h3>
<p>Shares of Tutor Perini were trading at $26.14 as of November 04. Over the last 52-week period, shares are up 261.88%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TPC/earnings"><strong>To track all earnings releases for Tutor Perini visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Tutor Perini Earnings Preview

<p>Finance of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOA#NYSE">FOA</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Finance of America to report an <strong>earnings per share</strong> (EPS) of $0.09.</p>
<p>Finance of America bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.15, leading to a 0.97% drop in the share price on the subsequent day.</p>
<p>Here's a look at Finance of America's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.20</td>
<td>-0.6</td>
<td>-0.8</td>
<td>-0.3</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.05</td>
<td>-0.3</td>
<td>-0.9</td>
<td>-1.1</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>-28.000000000000004%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840523_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Finance of America were trading at $12.85 as of November 04. Over the last 52-week period, shares are up 86.31%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/FOA/earnings"><strong>To track all earnings releases for Finance of America visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


An Overview of Finance of America's Earnings

<p>Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.27 by 3.7 percent. This is a 9.68 percent decrease over earnings of $0.31 per share from the same period last year.  The company reported quarterly sales of $1.11 billion which beat the analyst consensus estimate of $1.10 billion by 0.73 percent.  This is a 10.37 percent increase over sales of $1.00 billion the same period last year.</p>


Grocery Outlet Holding Q3 Adj $0.28 Beats $0.27 Estimate, Sales $1.11B Beat $1.10B Estimate

<p>Mercury Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.08) by 150 percent.  The company reported quarterly sales of $204.431 million which beat the analyst consensus estimate of $181.772 million by 12.47 percent.  This is a 12.95 percent increase over sales of $180.991 million the same period last year.</p>


MRCY

Mercury Sys Q1 2025 Adj. EPS $0.04 Beats $(0.08) Estimate, Sales $204.431M Beat $181.772M Estimate

<p>Across the recent three months, 5 analysts have shared their insights on Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $32.2, a high estimate of $37.00, and a low estimate of $26.00. This upward trend is evident, with the current average reflecting a 1.9% increase from the previous average price target of $31.60.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840515_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Teradata by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Austin Dietz</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$29.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Chirag Ved</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teradata. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teradata compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Teradata's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TDC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teradata analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Teradata</h2>
<p>Teradata Corp provides analytic data products and related services. The Company operates in data and analytics, which captures, integrates, stores, manages, and analyzes data of all types to answer business questions and deliver insight; and marketing applications, which offer marketing management products to help businesses win customer loyalty. Its solutions include components such as data warehousing, Asset optimization, Fraud prevention, Product innovation, and risk mitigation. A majority of the firm's revenue is generated in the United States.</p>
<h3>Teradata's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Teradata's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-5.63%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Teradata's net margin is impressive, surpassing industry averages. With a net margin of <strong>8.49%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>57.36%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.2%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Teradata's debt-to-equity ratio surpasses industry norms, standing at <strong>8.13</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Breaking Down Teradata: 5 Analysts Share Their Views

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were making margin calls with Yen.&nbsp;</p>



<p>Investors raced to sell off their stock and repay their loans, causing markets to crash.&nbsp; A weaker market allows investors to purchase stock at discounted prices. Indeed, the Healthcare sector is positioned to grow to $819 billion by 2027 at a robust 7% CAGR. One of the strongest growing sectors within the industry is health tech from generative AI use cases in the space.</p>



<p>Investors should take advantage of current market conditions and buy these Healthcare <a href="https://investorplace.com/industries/technology/artificial-intelligence/">AI stocks</a>.</p>



<h2>Twist Bioscience (TWST)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/11/twst1600-300x169.png" alt="Scientific handling a light microscope examines a laboratory sample for pharmaceutical bioscience research. Concept of science, laboratory and study of diseases. Twist Biosciences (TWST)"><div>Source: dhvstockphoto / Shutterstock.com</div></div><p><strong>Twist BioScience</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/twst-stock-quote/"><strong>TWST</strong></a></span>) is a biotechnology company that manufactures synthetic DNA products. <a href="https://finance.yahoo.com/quote/VST/analysis/"><em>Yahoo! Finance</em></a> reports seven analysts predicting a 1-year price range on TWST between $31.11 and $65.00, with an average price target of $51.91.&nbsp;</p>



<p>TWST reported financials that are characteristic of a biotechnology company. Q2 2024 revenue was strong, growing 27.81% YOY. However, the company has yet to return a profit this quarter, which has continued for the past year. There has been a trend of decreasing assets for the company, with total assets decreasing by 21.25% for Q2 2024. This marks the biggest decrease in the past year. However, the company&rsquo;s improving liquidity offers hope to investors. A 464.11% increase in free cash flow for Q2 2024 demonstrates management handling operational expenses.&nbsp;</p>



<p>The company may have a reversal in the future from a partnership with bitBiome. Both companies partnered to create an enzyme screening kit with pharmaceutical applications. The enzyme (transaminase) within the kit is specialized in synthesizing active pharmaceutical ingredients while serving as an environmentally safe alternative to other methods. TWST recently <a href="https://www.businesswire.com/news/home/20240604321380/en/Twist-Bioscience-Announces-Participation-in-Department-of-Commerce-Consortium-Dedicated-to-AI-Safety">joined</a> the U.S. AI Safety Institute Consortium (ASIC) to promote ethical AI development. Being environmentally and ethically conscious with upside potential makes TWST one of the healthcare AI stocks to buy.</p>



<h2>GE Healthcare (GEHC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/gehc1600-300x169.png" alt="GE Healthcare (GEHC) sign. GE Healthcare is an American company founded in 2014 and spun off from GE in 2023."><div>Source: testing / Shutterstock.com</div></div><p><strong>GE Healthcare</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/gehc-stock-quote/"><strong>GEHC</strong></a></span>) is a healthcare company that provides digital infrastructure, data analytics and decision support tools for various healthcare applications. <a href="https://finance.yahoo.com/quote/GEHC/analysis/"><em>Yahoo! Finance</em></a> reports 17 analysts predicting a 1-year price range on GEHC between $84.00 and $105.00, with an average price target of $93.95.&nbsp;</p>



<p>GEHC has solid financials for Q2 2024. The company barely missed on revenue but beat EPS expectations for the quarter. Revenue grew <a href="https://www.google.com/finance/quote/GEHC:NASDAQ">0.46%</a> year over year, and net profit margin grew 1.84% year over year. Additionally, management has improved its handling of operational expenditures, with free cash flow growing 131.81% year over year.&nbsp;</p>



<p>GEHC could be primed for a breakout with an <a href="https://aws.amazon.com/blogs/industries/aws-and-ge-healthcare-are-teaming-up-to-use-ai-to-improve-patient-care/">AWS partnership</a>. GEHC has partnered with <strong>Amazon</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/amzn-stock-quote/"><strong>AMZN</strong></a></span>) to develop AI models for healthcare applications. Specifically, the partnership aims to aggregate data from doctor notes, x-rays and other medical tests to develop healthcare insights. For instance, compositing data in such a manner streamlines future similar processes by establishing precedents of solutions and treatments. The potential this AWS partnership carries, alongside strong financials, makes GEHC one of the Healthcare AI stocks to watch.</p>



<h2>Clover Health (CLOV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/clov_clover_health_1600-300x169.png" alt="Clover Health (CLOV) company logo on a website with blurry stock market developments in the background, seen on a computer screen through a magnifying glass."><div>Source: Dennis Diatel / Shutterstock.com</div></div><p><strong>Clover Health </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/clov-stock-quote/"><strong>CLOV</strong></a></span>) is a healthcare company that provides Medicare Advantage insurance plans and operates as a direct contracting entity of the US government. <a href="https://finance.yahoo.com/quote/CLOV/analysis/">Yahoo Finance!</a> reports three analysts covering the stock with one buy rating and two hold ratings for July 2024.</p>



<p>CLOV reported very strong financials for Q2 2024. While revenue grew by <a href="https://www.google.com/finance/quote/CLOV:NASDAQ">7%</a>, the net profit margin grew by 75.33%. Moreover, this quarter marks the first quarter of positive net income for the company. As a result of such good earnings, management has improved full-year guidance. The level of improvement is best seen through EBITDA projections. Originally, EBITDA guidance was between a $20 million loss and gain; now, it is between $50 and $65 million.</p>



<p>The company has developed Clover Assistant, an AI assistant SaaS. The assistant is meant to serve as a clinical decision-making tool for payers and providers based on the patient&rsquo;s medical and financial data. Furthermore, the assistant tool allows CLOV to expand in areas that Medicare Advantage doesn&rsquo;t reach. It also has the potential for one-on-one use with Medicare Advantage patients as a recurring revenue stream on a use-by-use basis. Developments with AI and an improving financial outlook make CLOV one of the <a href="https://investorplace.com/industries/healthcare/">healthcare stocks</a> for investors to consider.</p>



<p><em>On the date of publication, Matthew Rodrigues&nbsp;<em>did not hold (either directly or indirectly) any positions in the securities mentioned in this article.</em>&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Matthew Rodrigues is a college student studying Business at UC Berkeley Haas. He believes detailed research and correct interpretation of current events is what leads to investment success.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/08/3-healthcare-ai-stocks-positioned-for-potential-breakthroughs/">3 Healthcare AI Stocks Positioned for Potential Breakthroughs</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Healthcare AI Stocks Positioned for Potential Breakthroughs

Invesco Main Street Small Cap Fund Q2 2024 Review

Invesco Small Cap Growth Fund Q2 2024 Review

Analysts have been eager to weigh in on the Healthcare sector with new ratings on CureVac (CVAC – Research Report), Vericel (VCEL – Research Report...

Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)

Interest Rate Regimes And ARKG: Underperformance Explained

Barclays analyst Luke Sergott maintained a Buy rating on Twist Bioscience (TWST – Research Report) today and set a price target of $55.00. The comp...

Barclays Sticks to Their Buy Rating for Twist Bioscience (TWST)

Analyst Catherine Ramsey Schulte of Robert W. Baird maintained a Buy rating on Twist Bioscience (TWST – Research Report), retaining the price targe...

Positive Outlook and Strong Pricing Strategy Justify Buy Rating for Twist Bioscience

XOMA Royalty Corporation (XOMA) has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation (TWST) to acquire...

Xoma enters $15M royalty monetization arrangement with Twist Bioscience

Twist Bioscience enters into purchase agreement with XOMA Royalty

Leerink Partners analyst Puneet Souda maintained a Hold rating on Twist Bioscience (TWST – Research Report) on October 22. The company's shares ope...

Leerink Partners Remains a Hold on Twist Bioscience (TWST)

ACHC

ADMA

ATKR

BLFS

CLOV

CRDO

CVAC

CYRX

CYTK

DAVA

EXAS

FRSH

FTAI

FTAIM

FTAIN

FTAIO

FTAIP

GEHC

GKOS

GLOB

GTES

GTLB

GWRE

INSP

ITGR

ITRI

KNSL

LSCC

MANH

MTSI

NTLA

ONON

ONTO

PACB

PFSI

PYCR

PZZA

RGEN

RMBS

SDGR

SITE

SITM

SKWD

SMCI

TMDX

TMXXF

VCEL

WING

XOMA

Press Releases

Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

Twist Bioscience to Present at Baird Global Healthcare Conference 2024

Twist Bioscience Releases 2024 Corporate Responsibility Report and Quantifies Carbon Footprint of Oligo Manufacturing Process for NGS Target Enrichment Panels

Twist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance

Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024

Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

Comments

Twist Bioscience

Twist Bioscience (TWST) 옵션

Twist Bioscience (NASDAQ:TWST) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌